Rapid Therapeutic Announces Record Order for 100,000 Units of its Metered Dose Inhalers Addressing $9.3 Billion CBD Market
Rapid’s RxoidTM branded inhalers deliver 98% bioavailable dose of CBD utilizing proprietary formulation blend
Dallas, TX – June 23, 2020 – Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL), a fully-reporting, early stage, emerging biotech company focused on manufacturing and marketing aerosol delivery of cannabinoids, including CBD, in the legal hemp and cannabis space using Metered Dose Inhalers (MDIs), announced today that RTSL received an order for a 100,000 unit wholesale order of its RxoidTM brand 5.0 mg proprietary CBD/CBG formulation which delivers a 98% bioavailable dose of CBD directly to the systemic blood stream.
Donal R. Schmidt, Jr., Esq., Chairman and CEO stated, “Our RxoidTM CBD Inhalers are currently being sold through doctors’ offices and in pharmacies across the United States and we are extremely pleased about our products’ acceptance throughout the medical community.”
About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)
RTSL has developed and perfected a new method of formulation and manufacturing to deliver pure CBD, CBG and/or THC and combinations thereof in legal jurisdictions to consumers through an FDA approved medical device known as a metered dose inhaler (MDI). The RxoidTM MDI product line is manufactured in compliance with cGMP on FDA approved equipment. Non-THC Cannabinoids are not yet approved by the FDA but are legal to consume in TX and many other states and export to legal foreign jurisdictions.
Properly formulated MDIs deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is the most efficient method of delivery of an API other than an IV. RTSL’s MDIs are a safe replacement for vape pens and delivers a 98% bioavailable dose of CBD and/or THC directly to the systemic blood stream. The current vape market in the US is estimated to be $5 Billion.
An MDI is the replacement for vape pens as it uses no heat and needs no dangerous ingredients to work. In addition, MDIs are less expensive than any other route of delivery measured by blood serum levels. They are however expensive to formulate and manufacture so that they legally and properly work as an MDI under FTC rules on truth and labeling.
RTSL markets its RxoidTM MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.
RTSL’s MDI products also can be purchased online at www.rxoid.com.
We encourage all customers to do their own research regarding cannabinoids, the use of MDI’s and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).
Visit our corporate website at www.rtslco.com.
This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Donal R. Schmidt, Jr., Esq.
Chairman and CEO
Source: Rapid Therapeutic Science Laboratories, Inc.